mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
4e-08 |
mRNA |
alisertib |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
6e-08 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
6e-08 |
mRNA |
STF-31 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
5e-07 |
mRNA |
LY-2183240 |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
6e-07 |
mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
6e-07 |
mRNA |
tipifarnib |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
2e-06 |
mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
6e-06 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
7e-06 |
mRNA |
Axitinib |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
1e-05 |